Research
Hormonal
Patients with prediabetes or drug-naive type 2 diabetes achieve significantly higher odds of substantial weight loss (≥10%) with Gelesis100 compared to placebo.
If you have prediabetes or early type 2 diabetes, Gelesis100 may be particularly effective for you, offering much higher odds of losing 10% or more of your body weight compared to those with normal blood sugar.
GoodQualifiesHIGH confidence
Patients with prediabetes or drug-naive type 2 diabetes had six times the odds of achieving ≥ 10% weight loss.
Why this rating
Subgroup analysis of a well-designed RCT.
Source
A Randomized, Double‐Blind, Placebo‐Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss
Frank L. Greenway et al. · Obesity · 2018
DOI 10.1002/oby.22347
rct · n=436Cited 175×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →